This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

ASCO Advocacy for Coverage of Off-Label Oncology Drug Uses

ASCO recently revised its policy on insurance coverage for off-label uses of oncology products. The issue of access to medically appropriate off-label use of cancer drugs and biologics has been a focus of ASCO advocacy for decades, and ASCO's efforts have demonstrably improved patient access to off-label drug uses.

Because of sponsorship by ASCO and other cancer advocates, federal payment programs like Medicare and Medicaid offer specific legislative support for reimbursement of medically appropriate off-label uses. Medicare Part B and Part D as well as Medicaid reimburse off-label uses that are listed in selected drug compendia, and Medicare Part B . . . [Click for More]